Basilea Pharmaceutica’s clinical pipeline expands further with the Phase I initiation for BAL2420, a novel antibiotic targeting Gram-negative bacterial infections such as caused by Enterobacteriaceae, including multidrug-resistant (MDR) strains such as E. coli and K. pneumoniae (50–70% of all Enter
